GSK Deal History & Licensing Activity
GSK is a large pharma headquartered in UK. Over the past three years, GSK has been involved in 45 licensing and acquisition transactions, with a primary focus on Other (8 deals). The company currently has 5 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
11
Active Trials
5
Top Modality
Other
Focus Area
Infectious Disease
GSK Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| JNJ-3989 | Arrowhead and Janssen | Other | Unknown | license | Apr 2026 |
| JNJ-3989 | Arrowhead | Oligonucleotides | Unknown | license | Apr 2026 |
| JNJ-3989 | Arrowhead Pharmaceuticals | Other | Unknown | license | Mar 2026 |
GSK Pipeline Focus
Therapeutic areas and modalities where GSK is most active based on deal history and clinical trial data.
Therapeutic Areas
GSK Strategic Signals
Key indicators of GSK's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
GSK Clinical Pipeline
GSK has 5 active clinical trials across 3 development phases.
2
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches GSK's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
About GSK Licensing & Deal Activity
GSK is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 45 deals over the past three years, GSK ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK include Infectious Disease (29 deals and trials), Oncology (23 deals and trials), Immunology (3 deals and trials), and Gastroenterology (2 deals and trials). In terms of modality, GSK has shown particular interest in other, oligonucleotides, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against GSK's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.